Cargando…

The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis

This research aimed to assess the effectiveness of combining induction chemotherapy (IC) or adjuvant chemotherapy (AC) with concurrent chemoradiotherapy (CCRT) in patients with T3-4N0-1M0 nasopharyngeal carcinoma (NPC). Before propensity score matching(PSM),we retrospectively collected 457 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Qiulu, Luo, Danjing, Li, Xiangde, Du, Qinghua, Liang, Qianfu, Liu, Wenqi, Li, Jian, Zhu, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653744/
https://www.ncbi.nlm.nih.gov/pubmed/37965924
http://dx.doi.org/10.1080/15384047.2023.2274121
_version_ 1785147815746338816
author Zhong, Qiulu
Luo, Danjing
Li, Xiangde
Du, Qinghua
Liang, Qianfu
Liu, Wenqi
Li, Jian
Zhu, Xiaodong
author_facet Zhong, Qiulu
Luo, Danjing
Li, Xiangde
Du, Qinghua
Liang, Qianfu
Liu, Wenqi
Li, Jian
Zhu, Xiaodong
author_sort Zhong, Qiulu
collection PubMed
description This research aimed to assess the effectiveness of combining induction chemotherapy (IC) or adjuvant chemotherapy (AC) with concurrent chemoradiotherapy (CCRT) in patients with T3-4N0-1M0 nasopharyngeal carcinoma (NPC). Before propensity score matching(PSM),we retrospectively collected 457 patients with T3-4N0-1M0 NPC treated with CCRT with or without IC/AC. PSM method selected 285 patients from two cohort(148 in CCRT±IC/AC group,137 in CCRT group). The 3-year overall survival(OS), locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) were estimated. The median follow-up was 41.03 months(range 2.13–94.67 months). No significant differences in 3 year-OS,LRFS and DMFS between CCRT±IC/AC group and CCRT group.Univariate analysis have shown that induction chemotherapy was significantly associated with 3 year LRFS(hazard ratio[HR] 0.214, 95%confidence interval[CI] 0.053–0.861,P = .030).Overall stage(HR 0.260, CI 0.078–0.870, P = .029) and T classification (HR 0.260, CI 0.078–0.870, P = .029)were significantly associated with OS.Multivariate analysis demonstrated no independent factors were related to 3-year OS,LRFS and DMFS. Subgroup analyses revealed that no significant survival differences in the two groups in patients with T3N1.In terms of T4N1 disease, patients received CCRT±IC/AC had lower 3-year DMFS than those treated with CCRT(90.4% vs 98.7%, P = .015). Adding IC or AC to CCRT did not significantly improve the prognosis of T3-4N0-1M0 NPC patients. Patients with T4N1M0 treated with CCRT had better DMFS than those received CCRT±IC/AC.However,more investigations should be confirmed the results.
format Online
Article
Text
id pubmed-10653744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-106537442023-11-15 The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis Zhong, Qiulu Luo, Danjing Li, Xiangde Du, Qinghua Liang, Qianfu Liu, Wenqi Li, Jian Zhu, Xiaodong Cancer Biol Ther Research Paper This research aimed to assess the effectiveness of combining induction chemotherapy (IC) or adjuvant chemotherapy (AC) with concurrent chemoradiotherapy (CCRT) in patients with T3-4N0-1M0 nasopharyngeal carcinoma (NPC). Before propensity score matching(PSM),we retrospectively collected 457 patients with T3-4N0-1M0 NPC treated with CCRT with or without IC/AC. PSM method selected 285 patients from two cohort(148 in CCRT±IC/AC group,137 in CCRT group). The 3-year overall survival(OS), locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) were estimated. The median follow-up was 41.03 months(range 2.13–94.67 months). No significant differences in 3 year-OS,LRFS and DMFS between CCRT±IC/AC group and CCRT group.Univariate analysis have shown that induction chemotherapy was significantly associated with 3 year LRFS(hazard ratio[HR] 0.214, 95%confidence interval[CI] 0.053–0.861,P = .030).Overall stage(HR 0.260, CI 0.078–0.870, P = .029) and T classification (HR 0.260, CI 0.078–0.870, P = .029)were significantly associated with OS.Multivariate analysis demonstrated no independent factors were related to 3-year OS,LRFS and DMFS. Subgroup analyses revealed that no significant survival differences in the two groups in patients with T3N1.In terms of T4N1 disease, patients received CCRT±IC/AC had lower 3-year DMFS than those treated with CCRT(90.4% vs 98.7%, P = .015). Adding IC or AC to CCRT did not significantly improve the prognosis of T3-4N0-1M0 NPC patients. Patients with T4N1M0 treated with CCRT had better DMFS than those received CCRT±IC/AC.However,more investigations should be confirmed the results. Taylor & Francis 2023-11-15 /pmc/articles/PMC10653744/ /pubmed/37965924 http://dx.doi.org/10.1080/15384047.2023.2274121 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Research Paper
Zhong, Qiulu
Luo, Danjing
Li, Xiangde
Du, Qinghua
Liang, Qianfu
Liu, Wenqi
Li, Jian
Zhu, Xiaodong
The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis
title The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis
title_full The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis
title_fullStr The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis
title_full_unstemmed The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis
title_short The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis
title_sort efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in t3-4n0-1m0 nasopharyngeal carcinoma: a propensity score-matched analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653744/
https://www.ncbi.nlm.nih.gov/pubmed/37965924
http://dx.doi.org/10.1080/15384047.2023.2274121
work_keys_str_mv AT zhongqiulu theefficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT luodanjing theefficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT lixiangde theefficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT duqinghua theefficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT liangqianfu theefficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT liuwenqi theefficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT lijian theefficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT zhuxiaodong theefficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT zhongqiulu efficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT luodanjing efficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT lixiangde efficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT duqinghua efficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT liangqianfu efficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT liuwenqi efficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT lijian efficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis
AT zhuxiaodong efficacyofinductionchemotherapyoradjuvantchemotherapyaddedtoconcurrentchemoradiotherapyint34n01m0nasopharyngealcarcinomaapropensityscorematchedanalysis